We are live on ! Find out more
RCKT icon

Rocket Pharmaceuticals
RCKT

175 hedge funds and large institutions have $1.83B invested in Rocket Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 79 increasing their positions, 44 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

224% more call options, than puts

Call options by funds: $24.7M | Put options by funds: $7.61M

80% more repeat investments, than reductions

Existing positions increased: 79 | Existing positions reduced: 44

75% more funds holding in top 10

Funds holding in top 10: 4 → 7 (+3)

71% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 17

21% more capital invested

Capital invested by funds: $1.52B → $1.83B (+$315M)

16.12% more ownership

Funds ownership: 94.9% → 111.02% (+16%)

7% more funds holding

Funds holding: 164 → 175 (+11)

Holders
175
Holders Change
+11
Holders Change %
+6.71%
% of All Funds
2.78%
Holding in Top 10
7
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+75%
% of All Funds
0.11%
New
29
Increased
79
Reduced
44
Closed
17
Calls
$24.7M
Puts
$7.61M
Net Calls
+$17.1M
Net Calls Change
+$13.5M

Top Buyers

1
Wellington Management Group
Wellington Management Group
Massachusetts
+$52.4M
2
LGM
Logos Global Management
California
+$31.4M
3
FLSM
Frazier Life Sciences Management
California
+$25.5M
4
ACA
Avoro Capital Advisors
New York
+$22.7M
5
MC
Maverick Capital
Texas
+$22.7M

Top Sellers

1
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$23.8M
2
Goldman Sachs
Goldman Sachs
New York
-$16.6M
3
CAM
Cormorant Asset Management
Massachusetts
-$7.61M
4
PHS
PFM Health Sciences
California
-$4.74M
5
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$2.54M
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$16M +$5.03M +276,627 +55%
JP Morgan Chase
27
JP Morgan Chase
New York
$15.6M -$971K -53,409 -7%
Russell Investments Group
28
Russell Investments Group
United Kingdom
$14.9M +$2.61M +143,695 +25%
Franklin Resources
29
Franklin Resources
California
$13.7M -$11.1K -612 -0.1%
IC
30
Ikarian Capital
Texas
$13.4M +$11.9M +654,726 New
Northern Trust
31
Northern Trust
Illinois
$11.9M +$165K +9,097 +2%
Goldman Sachs
32
Goldman Sachs
New York
$10.9M -$16.6M -911,191 -63%
MCM
33
M28 Capital Management
Connecticut
$10.7M -$1.95M -107,100 -17%
Charles Schwab
34
Charles Schwab
California
$9.59M +$597K +32,836 +8%
CAM
35
Cormorant Asset Management
Massachusetts
$9.22M -$7.61M -418,550 -48%
Comerica Bank
36
Comerica Bank
Texas
$9.02M +$8M +440,076 New
GC
37
GMT Capital
Georgia
$8.43M -$380K -20,900 -5%
Two Sigma Investments
38
Two Sigma Investments
New York
$8.12M +$6.4M +352,239 +799%
Mirae Asset Global Investments
39
Mirae Asset Global Investments
South Korea
$7.94M +$575K +31,653 +9%
ACP
40
Acuta Capital Partners
California
$7.42M +$1.01M +55,806 +18%
Fidelity Investments
41
Fidelity Investments
Massachusetts
$7.02M +$1.35M +74,431 +28%
Bank of America
42
Bank of America
North Carolina
$6.82M -$1.8M -98,949 -23%
WCM Investment Management
43
WCM Investment Management
California
$5.89M +$107K +5,867 +2%
UBS Group
44
UBS Group
Switzerland
$5.29M +$4.2M +230,812 +842%
Bank of New York Mellon
45
Bank of New York Mellon
New York
$5M +$795K +43,754 +22%
Norges Bank
46
Norges Bank
Norway
$4.99M – – –
Rafferty Asset Management
47
Rafferty Asset Management
New York
$4.95M +$156K +8,558 +4%
SAM
48
Sectoral Asset Management
Quebec, Canada
$4.65M +$659K +36,240 +19%
SFM
49
Sphera Funds Management
Israel
$4.28M -$490K -26,960 -11%
Renaissance Technologies
50
Renaissance Technologies
New York
$3.96M +$2.99M +164,600 +570%
1
2
3 4 5

RCKT Hedge Fund Activity: Q3 2023 in Review

175 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q3 2023, worth a combined $1.83B — up 21% from $1.52B a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new RCKT positions and 17 closed out — a net gain of 12 holders — while 79 added to existing stakes and 44 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $52.4M. The largest seller was Lord, Abbett & Co, exiting entirely with an estimated $23.8M sold.

  • 175 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q3 2023, up from 164 in Q2 2023.
  • Funds reported $1.83B of Rocket Pharmaceuticals stock for Q3 2023, up 21% quarter-over-quarter.
  • 29 funds opened new Rocket Pharmaceuticals positions in Q3 2023 and 17 closed out, a net change of +12 holders.
  • The largest Rocket Pharmaceuticals buyer in Q3 2023 was Wellington Management Group, an estimated $52.4M added.
  • The largest Rocket Pharmaceuticals seller in Q3 2023 was Lord, Abbett & Co, an estimated $23.8M sold.

Based on aggregated 13F filings for Q3 2023.